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Trials of Treatment-As-Prevention
Despite recent reductions in HIV incidence in several countries in sub-Saharan Africa, inci-
dence still remains at unacceptably high levels [1]. Effective control of the epidemic requires
more intensive prevention efforts. Two important approaches to address this goal are “combi-
nation prevention” [2], in which a number of partially effective interventions are combined to
achieve a substantial reduction in HIV incidence, and “treatment-as-prevention” (TasP), offer-
ing antiretroviral therapy (ART) to all HIV-infected adults irrespective of CD4+ T-cell count
to prevent onward transmission of HIV [3].
Mathematical models of the effects of TasP on population-level HIV incidence have produced
a wide range of projections [4–7]. There remain many uncertainties in model assumptions and,
critically, the impact of TasP at a population level depends on the coverage and uptake of HIV-
testing, linkage to care, treatment initiation and adherence—the “cascade of care” [8]. Rigorous
empirical studies are needed to determine whether TasP programmes can be implemented suc-
cessfully in practice; measure these important process indicators; assess the balance between
harms, costs, and benefits; and evaluate the impact of TasP on HIV incidence at population level.
Four large community trials are currently underway in South Africa [9,10], Zambia [10],
Botswana [11], and Kenya and Uganda [12]. The trials are studying a range of intervention
strategies with important differences in study design, but all four are measuring the impact of
TasP on HIV incidence using a community-randomised design.
In June 2014, Till Bärnighausen and colleagues [13] presented their views on the implica-
tions of the 2013 change in WHO ART guidelines for the TasP studies. Their main conclusions
were that as WHO guidelines are implemented [14], it will become unethical to continue the
trials because the new guidelines cannot be withheld in control communities; that if the new
guidelines are adopted in the control communities, the trials will no longer be adequately pow-
ered; and that alternative approaches such as pooling of data or adoption of stepped-wedge
study designs should be considered.
We believe that the article by Bärnighausen and colleagues contains a number of inaccurate
statements that compromise their conclusions. We discuss these issues in relation to the HPTN
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071 (PopART) trial that our study team is carrying out in 21 communities in Zambia and
South Africa to measure the impact of a combination prevention package, including universal
HIV testing and treatment, on population-level HIV incidence [10]. The HPTN 071 (PopART)
trial has three study arms (Fig. 1).
The communities in Arm A will receive the full “PopART” combination prevention pro-
gramme, including the offer of immediate initiation of ART for all HIV-infected adults irre-
spective of CD4 count. The PopART package includes home-based provision of HIV testing
and counselling, for all household members, referral of HIV-negative men for voluntary male
medical circumcision, screening for symptoms of tuberculosis and sexually transmitted infec-
tions, and referral of all HIV-infected individuals to the local health facility with active linkage,
follow-up, and ART adherence support. Arm B communities will receive the full PopART
package except that ART will be provided according to the prevailing local treatment guide-
lines. Arm C communities will continue to receive current standard of care.
Ethics of Trial Continuation
Bärnighausen and colleagues imply that when the study countries adopt the 2013 WHO treat-
ment guidelines, the TasP trial protocols would require the control communities to continue
receiving ART according to previous guidelines, with ART initiated at a CD4+ count of<350
cells/mm3. However, this assumption does not apply to HPTN 071 (PopART). The HPTN 071
trial protocol [10] states that any changes in treatment guidelines during the course of the trial
will be implemented in Arms B and C. Zambia has already adopted and is introducing the
2013 WHO guidelines into communities in Arms B and C, and South Africa is now following.
There is therefore no ethical concern with the continuation of the HPTN 071 trial with
adoption of the newWHO guidelines.
Inadequate Study Power
Bärnighausen and colleagues state that if the control arms of the TasP trials do switch to provid-
ing ART according to the 2013WHO guidelines, the studies will be underpowered for answer-
ing the primary study question, because of much smaller differences between the study arms.
Fig 1. Design of HPTN 071 (PopART) study showing the three study arms. This is a three-arm cluster-randomised trial with 21 communities (n 1.2
million total population). The three matched triplets (three in South Africa, four in Zambia) are illustrated on the right of the diagram, with one community per
study arm in each triplet.
doi:10.1371/journal.pmed.1001800.g001
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With respect to HPTN 071 (PopART), this is incorrect. The impact of HIV treatment on
transmission at a population level critically depends not only on the eligibility criteria for ART
initiation but also on several other key variables, including the uptake and coverage of HIV
testing, linkage to care, treatment initiation, and adherence. At each step in this cascade of care
there are substantial challenges in achieving high coverage and, without effective measures to
increase service uptake, the impact of any treatment programme (and of changes in ART eligi-
bility) will be limited.
The design of HPTN 071 (PopART) was informed by the results of mathematical modelling
of the projected impact of the interventions in Arms A and B under a range of assumptions
about uptake and coverage of the various components of the intervention [10,15]. At the re-
quest of the study’s Data and Safety Monitoring Board (DSMB), the model was used to evaluate
the effects on study power if the study countries were to adopt the 2013 WHO guidelines (S1
Text). In brief, the projections show only a small reduction in impact when Arm A is compared
with Arm C. This is because the effects of the change in eligibility criteria in Arm C will have
only a limited effect without substantial increases in uptake and coverage of testing and linkage.
The study power for the Arm A versus C comparison, the main study comparison, remains
very high. The difference between Arms B and C will increase following adoption of the new
guidelines, leading to higher power for this comparison. This is because more patients will be
eligible for treatment under the 2013 guidelines, but uptake and coverage will be higher in Arm
B due to the PopART home-based services. Finally, the difference between Arms A and B will
decrease. Both of these study arms benefit from the increased uptake and coverage achieved by
the PopART home-based services. Following adoption of the 2013 guidelines, there will be a
smaller number of HIV-infected individuals offered treatment in Arm A who would not be eli-
gible for treatment if in Arm B communities, reducing the power to demonstrate a difference
between Arms A and B.
Importance of Implementation Science to Determine Effectiveness
and Inform Policy on TasP
We agree with Bärnighausen and colleagues that an important objective of the TasP trials, in
addition to measuring effects on HIV incidence, is to provide useful data on the implementa-
tion of TasP to guide future policy and practice. TasP will only reach its potential effect on HIV
transmission if the uptake and coverage of HIV services is substantially expanded. Changing
treatment guidelines alone is not sufficient to assure the population level benefits of TasP. For
optimal impact, a large proportion of the population needs to know their HIV status (through
regular testing and re-testing), with effective linkage to appropriate treatment and care. We
therefore prefer the term “Universal Testing and Treatment” (UTT), which emphasises the im-
portance of the entire cascade of care, and not just treatment provision [16]. There remains an
urgent need for implementation science to provide information on how such HIV services can
most effectively be delivered in resource-poor settings, if TasP is found to be effective in reduc-
ing population level HIV incidence.
HPTN 071 (PopART) will provide valuable data on a wide range of process indicators.
Social science research will investigate the acceptability of the intervention to local communi-
ties, and case-control studies will explore factors related to uptake of the different steps of
the cascade with detailed costing exercises to determine overall cost-effectiveness. It cannot
be assumed that TasP carries no risks; the study will also measure behavioural risk disinhibi-
tion, ART toxicity, stigma, and drug resistance and balance these against effects on
HIV incidence.
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Alternative Approaches
In their article, Bärnighausen and colleagues propose two alternative approaches to take for-
ward the evaluation of TasP interventions.
They suggest first that it may be possible to pool data from the TasP trials to gain a more re-
liable overall measure of impact. This will be difficult, in practice, because of the substantial dif-
ferences in the interventions being tested and the study designs, as well as differences in HIV
transmission dynamics in different populations. We agree, however, that it will be important to
bring together the data from the four studies in careful analyses, supported by mathematical
modelling, to learn what we can from the findings. The investigators of the TasP trials have re-
solved to collaborate closely, facilitating future joint analyses.
Their second proposal is that if the trials cannot proceed to planned completion, it may be
possible for the researchers to work with Ministries of Health to agree on a phased introduction
of the new treatment guidelines according to a randomised stepped-wedge design. While this is
an interesting proposal, it is unlikely that countries would be willing to delay initiation of new
guidelines long enough for such a strategy to be feasible.
Conclusions
In summary, we believe that the conclusions of Bärnighausen and colleagues are based on mis-
understandings about the design of the HPTN 071 (PopART) trial. Because this trial is com-
mitted to providing care and treatment in Arms B and C according to the prevailing national
guidelines, there are no ethical concerns with the continuation of the trial. We also show that
the study, with its three-arm design, will remain highly powered for its main comparisons even
with adoption of the 2013 WHO guidelines in the study countries. We do not consider the im-
plications for other ongoing TasP trials in this article, but there may be value in exploring the
effects of changing guidelines on the power of those studies. Ultimately, there is an urgent need
to demonstrate effectiveness of the UTT approach at a population level and to rigorously evalu-
ate how best to safely and effectively deliver such an approach, which can then inform interna-
tional policy decisions.
Supporting Information
S1 Text. Mathematical model projections of impact of the HPTN 071 (PopART) trial inter-
ventions under the 2013 treatment guidelines. Note: This summary of the projections, pre-
pared for the trial’s Data and Safety Monitoring Board, is provided for information and has not
been subjected to journal peer-review.
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